Foghorn Therapeutics Inc. (FHTX)
NASDAQ: FHTX · Real-Time Price · USD
3.550
+0.030 (0.85%)
Mar 31, 2025, 1:15 PM EDT - Market open

Company Description

Foghorn Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of medicines targeting genetically determined dependencies within the chromatin regulatory system in the United States.

The company uses its proprietary Gene Traffic Control platform to identify, validate, and potentially drug targets within the system.

It is also developing therapies for mutant cancers, such as androgen receptor, positive prostate cancer, bladder cancer, Non-Small Cell Lung (NSCLC), as well as various lymphomas and leukemias; melanoma, endometrial, gastric, breast, colorectal, and pancreatic cancers; and dependent cancers, including prostate cancer and diffuse large b-cell lymphoma.

The company has collaboration agreement with Eli Lilly and Company for developing FHD-909, a selective ATPase inhibitor of BRM.

Foghorn Therapeutics Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Foghorn Therapeutics Inc.
Foghorn Therapeutics logo
Country United States
Founded 2015
IPO Date Oct 23, 2020
Industry Biotechnology
Sector Healthcare
Employees 112
CEO Adrian H. Gottschalk

Contact Details

Address:
500 Technology Square, Suite 700
Cambridge, Massachusetts 02139
United States
Phone 617 586 3100
Website foghorntx.com

Stock Details

Ticker Symbol FHTX
Exchange NASDAQ
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
IPO Price $16.00
CIK Code 0001822462
CUSIP Number 344174107
ISIN Number US3441741077
SIC Code 2834

Key Executives

Name Position
Karin Hellsvik Chief of Staff to the Chief Executive Officer, Vice President of Corporate Affairs and Investor Relations
Adrian H. B. Gottschalk President, Chief Executive Officer and Director
Kristian Humer M.B.A. Chief Financial Officer
Dr. Anna Rivkin Ph.D. Chief Business Officer
Dr. Gerald R. Crabtree M.d. Founder and Member of Scientific Advisory Board
Dr. Steven F. Bellon Ph.D. Chief Scientific Officer
Michael J. LaCascia J.D. Chief Legal Officer
Saurabh Sewak Ph.D. Vice President of Corporate Development
Carlos Costa Chief People Officer
Dr. Alfonso Quintas Cardama M.D. Chief Medical Officer

Latest SEC Filings

Date Type Title
Mar 24, 2025 8-K Current Report
Mar 20, 2025 8-K Current Report
Mar 20, 2025 424B5 Filing
Mar 6, 2025 10-K Annual Report
Mar 6, 2025 8-K Current Report
Feb 12, 2025 SCHEDULE 13G/A Filing
Feb 3, 2025 8-K Current Report
Jan 31, 2025 EFFECT Notice of Effectiveness
Jan 29, 2025 UPLOAD Filing
Jan 24, 2025 S-3 Registration statement under Securities Act of 1933